Enterochromaffin-like-cell (ECL) cell status by the score of oxyntic atrophy score (A, B), and by OLGA stage (C, D)
| ECL-N | A: Oxyntic atrophy score at T1 (p<0.00001) | B: Oxyntic atrophy score at T2 (p<0.00001) | ||||||||||
| G0 | G1 | G2 | G3 | Total | G0 | G1 | G2 | G3 | Total | |||
| ECL-N | 5 | 11 | 1 | 3 | 20 | 8 | 11 | 4 | 1 | 24 | ||
| ECL-DH | 3 | 13 | 14 | 137 | 167 | 1 | 8 | 10 | 132 | 151 | ||
| ECL-AH/D | 0 | 0 | 1 | 13 | 14 | 0 | 0 | 1 | 24 | 25 | ||
| T1-NET | 0 | 0 | 0 | 10 | 10 | 0 | 0 | 0 | 11 | 11 | ||
| Total | 8 | 24 | 16 | 163 | 211 | 9 | 19 | 15 | 168 | 211 | ||
| C: OLGA Stage at T1 (p<0.00001) | D: OLGA Stage at T2 (p<0.00001) | |||||||||||
| 0 | I | II | III | IV | T | 0 | I | II | III | IV | T | |
| ECL-N | 5 | 11 | 3 | 1 | 0 | 20 | 6 | 11 | 7 | 0 | 0 | 24 |
| ECL-DH | 3 | 12 | 152 | 0 | 0 | 167 | 1 | 8 | 133 | 9 | 0 | 151 |
| ECL-AH/D | 0 | 0 | 14 | 0 | 0 | 14 | 0 | 0 | 24 | 1 | 0 | 25 |
| T1-NET | 0 | 0 | 10 | 0 | 0 | 10 | 0 | 0 | 11 | 0 | 0 | 11 |
| Total | 8 | 23 | 179 | 1 | 0 | 211 | 7 | 19 | 175 | 10 | 0 | 211 |
The cells highlighted in grey shows cases that did not undergo any histological changes between T1 and T2. Cells in the space above and to the right of the grey cells show cases that worsened, whereas cells below and to the left of the grey cells show cases that underwent an improvement. T1: index biopsy set; T2: biopsy set at the end of the follow-up.
ECL (enterochromaffin like cell): ECL-status within normal limits; DH: diffuse hyperplasia (linear and nodular); AH/D: adenomatoid hyperplasia/dysplasia; T1-NET: Type 1 neuroendocrine tumours (NET). Histological atrophy score for the oxyntic biopsy set; G0=no atrophic changes; G1=atrophy involving 1%–29% of the mucosal specimens; G2=30%–59%; G3=≥60%.